Jacobs Bruce N.
Chief Financial Officer
Jacobs Bruce N. has filed 5 SEC Form 4 filings (21 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Jul 2, 2026.
On the most recent filing, Jacobs Bruce N. is listed as Chief Financial Officer at Kymera Therapeutics, Inc. Inside the rolling window, Jacobs Bruce N. reported no open-market purchases and 3 open-market sales totaling $10.0M in KYMR. The largest disclosed transaction in the window is a sale of 77,109 KYMR shares on Jun 30, 2026, worth $8.9M.
Companies traded
Other insiders at KYMR
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$10.0M
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 17, 2025 | KYMR | Sale | $4.0M |
Frequently asked questions
How many SEC Form 4 filings has Jacobs Bruce N. made?
Jacobs Bruce N. has filed 5 SEC Form 4 filings (21 transaction rows) across 1 company since 2025.
Which companies does Jacobs Bruce N. trade?
Jacobs Bruce N. has filed SEC Form 4 disclosures for 1 company, including KYMR.
When was Jacobs Bruce N.'s most recent SEC Form 4 filing?
Jacobs Bruce N.'s most recent SEC Form 4 filing on Tracefour is dated Jul 2, 2026.
What is Jacobs Bruce N.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Jacobs Bruce N. is listed as Chief Financial Officer.
What is Jacobs Bruce N.'s total buy and sell value in the current window?
Inside the rolling retention window, Jacobs Bruce N. bought $0 and sold $10.0M based on SEC Form 4 filings.
What was Jacobs Bruce N.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 77,109 KYMR shares on 2026-06-30, worth $8.9M, per SEC Form 4 filings.